| Urinary MicroRNAs as biomarkers of urological cancers: a systematic review A Aveta, S Cilio, R Contieri, G Spena, L Napolitano, C Manfredi, A Franco, ... International Journal of Molecular Sciences 24 (13), 10846, 2023 | 59 | 2023 |
| Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer M Ferro, B Barone, F Crocetto, G Lucarelli, GM Busetto, F Del Giudice, ... Urologic Oncology: Seminars and Original Investigations 40 (11), 490. e13 …, 2022 | 40 | 2022 |
| Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience N Frego, A Saita, P Casale, P Diana, R Contieri, PP Avolio, M Lazzeri, ... World Journal of Urology, 1-7, 2021 | 32 | 2021 |
| Long-term follow-up and factors associated with active surveillance failure for patients with non–muscle-invasive bladder cancer: the Bladder Cancer Italian Active Surveillance … R Contieri, M Paciotti, G Lughezzani, NM Buffi, N Frego, P Diana, ... European Urology Oncology 5 (2), 251-255, 2022 | 26 | 2022 |
| Modified Glasgow prognostic score as a predictor of recurrence in patients with high grade non-muscle invasive bladder cancer undergoing intravesical bacillus Calmette–Guerin … M Ferro, OS Tătaru, G Musi, G Lucarelli, AR Abu Farhan, F Cantiello, ... Diagnostics 12 (3), 586, 2022 | 26 | 2022 |
| The impact of SARS-CoV-2 pandemic on time to primary, secondary resection and adjuvant intravesical therapy in patients with high-risk non-muscle invasive bladder cancer: a … M Ferro, F Del Giudice, G Carrieri, GM Busetto, L Cormio, R Hurle, ... Cancers 13 (21), 5276, 2021 | 23 | 2021 |
| Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non–muscle-invasive bladder cancer after BCG … R Hurle, R Contieri, P Casale, E Morenghi, A Saita, N Buffi, G Lughezzani, ... Urologic Oncology: Seminars and Original Investigations 39 (3), 195. e7-195. e13, 2021 | 21 | 2021 |
| Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancer W Krajewski, J Aumatell, JD Subiela, Ł Nowak, A Tukiendorf, M Moschini, ... Urologic Oncology: Seminars and Original Investigations 40 (11), 491. e11 …, 2022 | 19 | 2022 |
| Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG. R Contieri, R Hurle, M Paciotti, P Casale, A Saita, F Porpiglia, C Fiori, ... Minerva Urology and Nephrology, 2022 | 19 | 2022 |
| Long-term follow-up after en bloc transurethral resection of non–muscle-invasive bladder cancer: Results from a single-center experience M Paciotti, P Casale, P Colombo, V Fasulo, A Saita, G Lughezzani, ... European Urology Open Science 26, 64-71, 2021 | 18 | 2021 |
| Outcomes and Techniques of Robotic-Assisted Partial Nephrectomy (RAPN) for Renal Hilar Masses: A Comprehensive Systematic Review SD Pandolfo, Z Wu, R Campi, R Bertolo, D Amparore, A Mari, P Verze, ... Cancers 16 (4), 693, 2024 | 17 | 2024 |
| Oncological outcomes for patients with European Association of Urology very high-risk non–muscle-invasive bladder cancer treated with bacillus Calmette-Guérin or early radical … R Contieri, PJ Hensley, WS Tan, V Grajales, K Bree, ... European Urology Oncology 6 (6), 590-596, 2023 | 17 | 2023 |
| Survival outcomes after immediate radical cystectomy versus conservative management with Bacillus Calmette-Guérin among T1 high-grade micropapillary bladder cancer patients … C Lonati, P Baumeister, L Afferi, A Mari, A Minervini, W Krajewski, S Azizi, ... European Urology Focus 8 (5), 1270-1277, 2022 | 17 | 2022 |
| Xpert bladder cancer monitor may avoid cystoscopies in patients under “active surveillance” for recurrent bladder cancer (BIAS project): longitudinal cohort study V Fasulo, M Paciotti, M Lazzeri, R Contieri, P Casale, A Saita, ... Frontiers in Oncology 12, 832835, 2022 | 17 | 2022 |
| Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis F Petrelli, P Giannatempo, C Maccagnano, R Contieri, R Hurle Cancer Treatment and Research Communications 27, 100369, 2021 | 17 | 2021 |
| Intravesical gemcitabine as bladder‐preserving treatment for BCG unresponsive non‐muscle‐invasive bladder cancer. Results from a single‐arm, open‐label study R Hurle, P Casale, E Morenghi, A Saita, N Buffi, G Lughezzani, ... BJUI compass 1 (4), 126-132, 2020 | 15 | 2020 |
| Bladder-sparing treatment in patients with bacillus Calmette-Guerin–unresponsive non–muscle-invasive bladder cancer: an analysis of long-term survival outcomes WS Tan, V Grajales, R Contieri, P Hensley, K Bree, P Msaouel, CC Guo, ... European Urology Open Science 53, 16-22, 2023 | 13 | 2023 |
| International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer scoring system predicts outcomes of patients on active surveillance WS Tan, R Contieri, NM Buffi, G Lughezzani, V Grajales, M Soloway, ... The Journal of Urology 210 (5), 763-770, 2023 | 11 | 2023 |
| Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy? A Cimadamore, C Lonati, E Di Trapani, O De Cobelli, M Rink, S Zamboni, ... Urologic Oncology: Seminars and Original Investigations 40 (6), 273. e11-273 …, 2022 | 11 | 2022 |
| Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration C Lonati, L Afferi, A Mari, A Minervini, W Krajewski, M Borghesi, ... World Journal of Urology 40 (5), 1167-1174, 2022 | 11 | 2022 |